# Limited Competition: Resources and Workforce Development for the Regional Biocontainment Laboratories (UC7 Clinical Trial Not Allowed)

Source: https://welltoldgrants.com/grants/rfa-ai-22-075-limited-competition-resources-and-workforce-development-for/  
Official notice: https://www.grants.gov/search-results-detail/344925

> National Institutes of Health offered grants of up to $1.0 million to small businesses. Applications closed on February 22, 2023.

| Field | Value |
|---|---|
| Opportunity number | RFA-AI-22-075 |
| Agency | National Institutes of Health |
| Status | Forecast |
| Deadline | February 22, 2023 |
| Award ceiling | $1.0 million |
| Award floor | not stated |
| Expected awards | not stated |
| Total funding | not stated |
| Cost sharing | not required |
| Assistance Listings | 93.855 |

## Who can apply

- Small businesses

Other Eligible Applicants include the following: Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are not allowed. See full Funding Opportunity Announcement for additional details on eligibility

## What the grant funds

The goal of this Funding Opportunity Announcement (FOA) is to provide support to the 12 Regional Biocontainment Laboratories (RBLs) previously constructed with NIAID support to enable them to develop and maintain resources, staff, and facilities necessary to address biodefense agents, emerging infectious diseases, and pandemic preparedness in line with NIAID priorities. Operations support is provided for facility maintenance and operations, as well as Biosafety Level 3 (BSL-3) practices support for personnel working in and around BSL-3 space and associated building systems. An optional component would allow the RBLs to provide specialized services essential to support BSL3 activities. The RBLs will serve as regional resources for efforts in conducting pre-clinical and laboratory (in vitro and in vivo) research and testing on hazardous biological agents in support of NIAIDs biodefense, emerging infectious diseases, and pandemic preparedness research efforts.

## Questions people ask

### Is RFA-AI-22-075 still open?

No. It closed on February 22, 2023.

### Who can apply for Limited Competition: Resources and Workforce Development for the Regional Biocontainment Laboratories (UC7 Clinical Trial Not Allowed)?

National Institutes of Health accepted applications from small businesses. The notice adds further conditions, so read its eligibility section.

### What is the deadline for Limited Competition: Resources and Workforce Development for the Regional Biocontainment Laboratories (UC7 Clinical Trial Not Allowed)?

Closed February 22, 2023. Applications are no longer accepted; the program's newer notices are on this page when there are any.

### How much funding is available?

Awards of up to $1.0 million each.

### Who has been funded under RFA-AI-22-075?

NIH RePORTER lists 12 projects funded under RFA-AI-22-075 in fiscal 2023 to 2026, at 12 institutions. The most were at Tufts University Boston, Colorado State University, University of Pittsburgh at Pittsburgh.

### Who has won Allergy and Infectious Diseases Research grants before?

The largest recipients over five fiscal years were Fred Hutchinson Cancer Center, Duke University, University of California, Los Angeles. The program made 13,282 awards worth $22 billion in that time.